Skip to main content
Cardio Ed

Cardio Ed

By The Cardio Ed Podcast

Let's talk about contemporary issues in cardiology.
Let's discuss and learn together.
Join me in this quest for knowledge in cardiology.
Available on
Apple Podcasts Logo
Castbox Logo
Google Podcasts Logo
Pocket Casts Logo
RadioPublic Logo
Spotify Logo
Currently playing episode

Revascularization: techniques,hardwares &procedures in PCI. 2021ACC/AHA/SCAI guidelines

Cardio EdFeb 02, 2022

00:00
17:23
Revascularization: techniques,hardwares &procedures in PCI. 2021ACC/AHA/SCAI guidelines

Revascularization: techniques,hardwares &procedures in PCI. 2021ACC/AHA/SCAI guidelines

Procedures & Techniques of PCI. 2021 ACC/AHA/SCAI guidelines. A discussion on Vascular access, stent types, Thrombectomy, CTO PCI, ISR, SVG - PCI, Hemodynamic Support for #PCI and many such topics. We have been discussing the 2021 #coronary revascularization guidelines given by #ACC. This is the 6th and the last video in this series. in this video we discuss about the following Vascular Access Stent types Thrombectomy Intravascular Imaging (IVUS & OCT) Calcified lesion In stent restenosis CTO PCI PCI for patients after CABG (SVG PCI) Hemodynamic Support for PCI In order to learn more about Vascular Access, Stent types, Thrombectomy, Intravascular Imaging (IVUS & OCT), treatment of Calcified lesion, In stent restenosis, CTO PCI, PCI for patients after CABG (SVG PCI), Hemodynamic Support for PCI watch the video. A discussion on guidelines given by the following bodies. #americanheartassociation #acc2021 #scai Related and recommended video In stent restenosis https://youtu.be/4poE6E5yZJc Revascularization in stable CAD -1 https://youtu.be/ZIxUpDY32MQ Revascularization in stable CAD -2 https://youtu.be/fyHM6KJ9B_M Revascularization in NSTE- ACS https://youtu.be/hul1sRuxezg Revascularization in STEMI https://youtu.be/SknUePl9KzQ Antiplatelet Therapy before, during & after Revascularization https://youtu.be/YUI6C9XHyyo Revascularization in special situations https://youtu.be/5e6rox6oJ2A This was a complete discussion on the recommendations from: American Heart Association American College of Cardiology. Society for Cardiovascular Angiography and Interventions.
Feb 02, 202217:23
Revascularization in special situations.2021 ACC/AHA/SCAI GUIDELINES on Myocardial Revascularization

Revascularization in special situations.2021 ACC/AHA/SCAI GUIDELINES on Myocardial Revascularization

Revascularization in special situations - #pregnancy, old age, chronic kidney disease, cardiac allograft; revascularization to prevent ventricular tachycardia. Here is a discussion from 2021 ACC/AHA/SCAI GUIDELINES on Myocardial Revascularization. What to do in case of pregnancy? What to do in patients with #CKD? What to do in patients with old age? What to do in patients with ventricular tachycardia? What to do in patients with spontaneous #coronary artery dissection #SCAD? What to do in patients with cardiac allograft? This video and Podcast answer the appropriate revascularization modality in patients with pregnancy, old age, chronic kidney disease, cardiac allograft and ventricular tachycardia. This podcast is part of lectures we are doing on 2021 ACC/AHA/SCAI GUIDELINES on Myocardial Revascularization. Related discussions: Antiplatelets before/ during & after Revascularization. https://youtu.be/YUI6C9XHyyo Revascularization in STEMI https://youtu.be/SknUePl9KzQ Revascularization in NSTE-ACS https://youtu.be/hul1sRuxezg Revascularization in stable CAD https://youtu.be/fyHM6KJ9B_M Cardio Ed podcast is available on all major podcast platforms. Do follow and share the podcast and videos.
Jan 22, 202215:57
ANTIPLATELET THERAPY AFTER PCI. 2021 ACC/AHA/SCAI GUIDELINES

ANTIPLATELET THERAPY AFTER PCI. 2021 ACC/AHA/SCAI GUIDELINES

ANTIPLATELET THERAPY BEFORE / DURING & AFTER PCI and CABG - 2021 ACC/AHA/SCAI GUIDELINES. A lot has changed in the field of Antiplatelet and antithrombotic therapy in patients undergoing #PCI or CABG. New evidence from trials like TWILIGHT trial, STOPDAPT trial, GLASSY & GLOBAL LEADER trial has made us reconsider what is optimal Antiplatelet Therapy for patients undergoing CABG and PCI. The new ACC/ AHA/ SCAI Guidelines have considered these evidence and have given new recommendations for patients undergoing #coronary revascularization. Let's take a deep dive into the topic. We have discussed 2021 ACC/AHA/SCAI GUIDELINES under various headings in the following videos and podcast. Do have a look. Revascularization in STEMI https://youtu.be/SknUePl9KzQ Revascularization in NSTE-ACS https://youtu.be/hul1sRuxezg Revascularization in stable CAD https://youtu.be/fyHM6KJ9B_M
Jan 22, 202227:39
TOMAHAWK trial. Angiography after Cardiac Arrest without ST elevation. NEJM 2021. ESC 2021

TOMAHAWK trial. Angiography after Cardiac Arrest without ST elevation. NEJM 2021. ESC 2021

TOMAHAWK trial or Angiography after Out-of-Hospital Cardiac Arrest without ST-Segment Elevation trial was recently published in #NEJM New England journal of Medicine and presented at the European Society of Cardiology Virtual Congress in 2021. It tested the strategy of immediate coronary angiography vs delayed or selective coronary angiography in patients with OHCA or Out of Hospital Cardiac Arrest patients without ST segment elevation. Related Topic previously discussed: Therapeutic Hypothermia after Cardiac Arrest. TTM-2 trial https://youtu.be/FKdvKcr8bEs Follow Cardio-Ed for more content. https://www.thecardioedblog.com Follow social media profiles getting updates regarding new videos / podcast https://twitter.com/drShaileshSingh?s=09 https://www.facebook.com/CardiologyEd/ Cardio-Ed is now available on Apple Poscast, Google Podcast, Spotify and other major podcast platforms too. Now you can stay updated on the go. Listen to episodes. Here are the links. Apple https://podcasts.apple.com/us/podcast/cardio-ed/id1570745864 Google Podcast https://podcasts.google.com/feed/aHR0cHM6Ly9hbmNob3IuZm0vcy81ZDRiOTgwMC9wb2RjYXN0L3Jzcw Spotify https://open.spotify.com/show/3SLQ2g4Ii8hdFiy7i8LMRp?si=hWgPgwliQ5a5RY_nz-Q22g&utm_source=copy-link Amazon Music https://music.amazon.in/podcasts/4215cfdf-5121-438e-b355-14eaabed41e5/CARDIOED?ref=dm_sh_vn5xvDArGZGRCTh8YpK3Mdtff Stitcher https://www.stitcher.com/podcast/cardioed music –––––––––––––––––––––––––––––– California by MusicbyAden https://soundcloud.com/musicbyaden Creative Commons — Attribution-ShareAlike 3.0 Unported — CC BY-SA 3.0 Free Download / Stream: https://bit.ly/al-california Music promoted by Audio Library https://youtu.be/oZ3vUFdPAjI
Jan 12, 202209:46
PARADISE MI Trial. ARNI in Acute Myocardial Infarction. NEJM 2021/ ACC 2021

PARADISE MI Trial. ARNI in Acute Myocardial Infarction. NEJM 2021/ ACC 2021

PARADISE MI Trial. ARNI in Acute Myocardial Infarction. NEJM 2021/ ACC 2021
Jan 08, 202205:30
Revascularization - stable CAD. ACC/AHA/SCAI guidelines 2021

Revascularization - stable CAD. ACC/AHA/SCAI guidelines 2021

Revascularization in stable CAD. ACC/AHA/SCAI guidelines 2021. Revascularization in stable CAD (coronary artery disease) had been a matter of debate in the field of Interventional Cardiology and cardiac surgery. What to do in patients with single vessel disease? What to do in patients with triple vessel disease? What to do in patients with Diabetes? Should the patients receive medical treatment only? Should the patients be managed by stenting? Should the patients be managed by CABG? This was a huge 100+ page document, so breaking it down for easier discussion into multiple parts. This is third of many videos about to come on this document by ACC/AHA/SCAI. #Coronary #AHA2021 #americanheartassociation current evidence in the stable CAD - #ISCHEMIA trial, #FREEDOM trial, #ORBITA trial, #COURAGE trial and many other such trials. we had previously discussed revascularization in stable CAD & various studies related to it in this video. Revascularization in stable CAD-1 https://youtu.be/ZIxUpDY32MQ #cardiology #CardioEd #cardiacsurgery #CardiacSurgeon #ischemiatrial Follow Cardio-Ed for more content. https://m.youtube.com/channel/UCVxInTblTpoy-THMuSxNyvw/videos AVATAR trial. https://youtu.be/yVy2muQkOyA REVERSE IT trial https://youtu.be/gdQHuA0mT3E Revascularization in stable CAD https://youtu.be/ZIxUpDY32MQ Half dose DOAC vs standard antithrombotic therapy after LAA occlusion https://youtu.be/6xd6G2ieIWU ISCHEMIA trial and contemporary PCI practice in US https://youtu.be/DnUdv5-q9Ts FAME 3 trial. https://youtu.be/3x6qNXhNlko ACTIVATION trial https://youtu.be/cA75MKO_Ha8 EMPEROR PRESERVED trial https://youtu.be/Zq4fprAcQPI Treatment of HFpEF https://youtu.be/M9os7eYNI20 The role of SGLT2 Inhibitors in this video. SGLT2inhibitors in heart failure. https://youtu.be/T5Zhof_6-3Q Device related thrombosis after LAA occlusion https://youtu.be/ghSvuGsK06k Abelacimab for prevention of venous thromboembolism https://youtu.be/2_gaHMTz2T8 ADAPTABLE trial. Aspirin for secondary prevention https://youtu.be/94lhXi3nQUs REHAB-HF trial. Cardiac rehabilitation in heart failure https://youtu.be/EMyiA-KrbP0 GALACTIC HF trial. Omecamtiv mecarbil in heart failure https://youtu.be/H7F42lhe5ao In-stent restenosis https://youtu.be/4poE6E5yZJc TTM-2 trial. Therapeutic hypothermia in cardiac arrest https://youtu.be/FKdvKcr8bEs FLOWER-MI trial. FFR in STEMI https://youtu.be/ijJRqgbda4Q LAAOS-3 trial. Left atrial appendage occlusion in cardiac surgery https://youtu.be/mc4j7mLw22Q Cardio-Ed is now available on Apple Poscast, Google Podcast, Spotify and other major podcast platforms too. Now you can stay updated on the go. Listen to episodes.(New episodes should be immediately avaliable on Spotify; would feature on other platforms in a while). Here are the links. Apple https://podcasts.apple.com/us/podcast/cardio-ed/id1570745864 Google Podcast https://podcasts.google.com/feed/aHR0cHM6Ly9hbmNob3IuZm0vcy81ZDRiOTgwMC9wb2RjYXN0L3Jzcw Spotify: https://open.spotify.com/show/3SLQ2g4Ii8hdFiy7i8LMRp?si=hWgPgwliQ5a5RY_nz-Q22g&utm_source=copy-link Amazon Music https://music.amazon.in/podcasts/4215cfdf-5121-438e-b355-14eaabed41e5/CARDIOED?ref=dm_sh_vn5xvDArGZGRCTh8YpK3Mdtff Stitcher: https://www.stitcher.com/podcast/cardioed Podcastaddict: https://podcastaddict.com/podcast/3368070 Breaker: https://www.breaker.audio/cardio-ed PocketCasts https://pca.st/bprb5899 RadioPublic https://radiopublic.com/cardioed-Woje3A Podcast Index https://podcastindex.org/podcast/3933141 Player FM https://player.fm/series/cardio-ed Listen Notes https://www.listennotes.com/podcasts/cardio-ed-cardio-ed-Jk3r1sq5_VF/
Jan 06, 202223:15
Revascularization in NSTE-ACS. 2021 ACC/ AHA/ SCAI Guidelines myocardial revascularization

Revascularization in NSTE-ACS. 2021 ACC/ AHA/ SCAI Guidelines myocardial revascularization

Revascularization in NSTE- ACS (Non ST segment elevation acute coronary syndrome). 2021 ACC/AHA/STS/SCAI guidelines for myocardial revascularization -2.

A discussion on every old and new concept in 2021 guidelines for myocardial revascularization.
This was a huge 100+ page document, so breaking it down for easier discussion into multiple parts.
This is second of many videos about to come on this document by ACC/AHA/SCAI.

#Coronary #AHA2021 #ACC2021 #SCAI2021 #americanheartassociation
#americancollegeofcardiology #cardio #cardiology #interventionalcardiology #interventions #NSTEACS #NSTEMI #Unstableangina #myocardialinfarction #meded #cardiovascular
Dec 26, 202105:57
Revascularization in STEMI. 2021 ACC/ AHA/ SCAI Guidelines

Revascularization in STEMI. 2021 ACC/ AHA/ SCAI Guidelines

Revascularization in STEMI. 2021 ACC/AHA/STS/SCAI guidelines for myocardial revascularization -I.

A discussion on every old and new concept in 2021 guidelines for myocardial revascularization.
This was a huge 100+ page document, so breaking it down for easier discussion into multiple parts.
This is first of many videos about to come on this document by ACC/AHA/SCAI.

#Coronary #AHA2021 #americanheartassociation #cardio #cardiology #interventionalcardiology #interventions #STEMI #myocardialinfarction #meded #cardiovascular
Dec 14, 202116:42
EMPULSE Trial. EMPAGLIFLOZIN in Acute Heart Failure.

EMPULSE Trial. EMPAGLIFLOZIN in Acute Heart Failure.

EMPULSE Trial. EMPAGLIFLOZIN in Acute Heart Failure.EMPULSE TRIAL. EMPAGLIFLOZIN in patients with acute decompensated heart failure.

#heart
#cad
#heartfailure #aha
#cardioed
#cardio
#cardiologist #cardiologia #cardiologie #cardiovascular
Dec 05, 202106:58
FFR. FRACTIONAL FLOW RESERVE. EVIDENCE & APPLICATIONS

FFR. FRACTIONAL FLOW RESERVE. EVIDENCE & APPLICATIONS

Fractional Flow Reserve or FFR. #FFR. Fractional Flow Reserve is useful for assessment and management of intermediate coronary lesions, left main interventions, multivessel disease and stable CAD.

#FractionalFlowReserve.
Here is a discussion on applications of Fractional Flow Reserve OR FFR in Interventional Cardiology and the various trials supporting the use of FFR - FAME trial, FAME 2 trial, DEFER trial, DANAMI 3 PRIMULTI trial, COMPARE ACUTE trial, FAMOUS NSTEMI trial, FAME 3 trial, FLOWER MI trial.

#Coronary #Physiology for #coronary #intervention.
Dec 05, 202133:25
CHIEF HF Trial. CANAGLIFLOZIN in HEART FAILURE. AHA 2021

CHIEF HF Trial. CANAGLIFLOZIN in HEART FAILURE. AHA 2021

CHIEF HF Trial was recently presented at the AHA 2021 meeting. It tested an #SGLT2Inhibitor #CANAGLIFLOZIN in #HEARTFAILURE.

CHIEF HF Trial or CANAGLIFLOZIN in HEART FAILURE which was recently presented at AHA 2021 is yet to be published.

If you were searching about CHIEF HF Trial or role of CANAGLIFLOZIN in HEART FAILURE you can find it in this video. The authors first presented its results in AHA 2021.
Nov 25, 202104:14
RAPID CABG Trial. AHA 2021. EARLY CABG AFTER TICAGRELOR..

RAPID CABG Trial. AHA 2021. EARLY CABG AFTER TICAGRELOR..

RAPID CABG Trial was recently presented at the AHA 2021. It tested the strategy of EARLY CABG AFTER TICAGRELOR vs delayed CABG after Ticagrelor administration.

Nov 22, 202107:05
CTCR - MVS Trial. Tricuspid valve repair in patients undergoing Mitral Valve surgery. AHA 2021.

CTCR - MVS Trial. Tricuspid valve repair in patients undergoing Mitral Valve surgery. AHA 2021.

CTCR - MVS Trial. Tricuspid valve repair in patients undergoing Mitral Valve surgery. AHA 2021. NEJM 2021.
Nov 21, 202108:49
REVERSE- IT Trial. Bentracimab for ticagrelor reversal. AHA 2021

REVERSE- IT Trial. Bentracimab for ticagrelor reversal. AHA 2021

REVERSE- IT Trial. Bentracimab for ticagrelor reversal. AHA 2021
Nov 19, 202106:10
AVATAR Trial. Aortic valve replacement in Asymptomatic Severe Aortic Stenosis. AHA 2021

AVATAR Trial. Aortic valve replacement in Asymptomatic Severe Aortic Stenosis. AHA 2021

AVATAR Trial. Aortic valve replacement in Asymptomatic Severe Aortic Stenosis. AHA 2021.
Nov 18, 202111:20
Revascularization in stable CAD -1.

Revascularization in stable CAD -1.

How to manage patients with stable coronary artery disease. First part of the discussion - a look at all the contemporary data we have.
Nov 17, 202119:00
Best Antithrombotic Regimen after Watchman device? - JACC Interventions

Best Antithrombotic Regimen after Watchman device? - JACC Interventions

Best Antithrombotic Regimen after Watchman device? - JACC Interventions
Nov 15, 202110:20
PCI in U.S. for stable CAD vs ISCHEMIA trial population - How different? (JACC Interventions)

PCI in U.S. for stable CAD vs ISCHEMIA trial population - How different? (JACC Interventions)

In the latest edition of #JACC Interventions, this recently published study titled "Comparison of Patients Undergoing Percutaneous Coronary Intervention in Contemporary U.S. Practice With ISCHEMIA Trial Population" compared the patients in United States undergoing PCI for stable #coronary artery disease (#CAD) with recently published #ISCHEMIA study. We got of new insights from data from this registry. Let's find out.
Nov 14, 202105:45
ACTIVATION trial. PCI before TAVR - Should we do it?

ACTIVATION trial. PCI before TAVR - Should we do it?

The percutaneous coronary intervention prior to transcatheter aortic valve implantation (ACTIVATION) trial (
#ACTIVATIONtrial) tested the strategy the #PCI before #TAVR Vs #TAVR without #PCI in patients with significant #CAD without significant #angina. Unfortunately the trial was terminated because of slow enrollment. Yet, it shed light on important issue in the holistic management of #TAVR patients. With newer evidences for management for #TAVR patients, more and more people are going to be screened for and offered #TAVR. Management of concomitant #CAD in these patients is an important issue. In this video we discuss about the #ActivationTrial and what to do for #CAD in patients undergoing #TAVR.


Nov 13, 202108:14
EMPEROR PRESERVED trial. Empagliflozin in HFpEF patients - Finally something works in HFpEF.

EMPEROR PRESERVED trial. Empagliflozin in HFpEF patients - Finally something works in HFpEF.

#EMPEROR PRESERVED trial was recently published in #NEJM in 2021. It was also presented at #ESC2021.


Heart Failure with Preserved Ejection Fraction (#HFpEF) is responsible of more than half of the cases of heart failure.
It is a difficult to diagnose and difficult to treat condition.

#Emplagliflozin and #dapagloflozin are 2 #SGLT2inhibitors have been found to be useful drugs in the management of #heart failure with reduced ejection fraction. The EMPEROR REDUCED and DAPA-HF trials have proven the efficacy of both these drugs in #heartfailure with reduced ejection (HFrEF).
The #EMPEROR PRESERVED trial tested that whether #emplagliflozin can be useful in the management of Heart Failure with Preserved Ejection Fraction (#HFpEF).

Nov 13, 202106:29
FAME - 3 trial. FFR guided PCI vs CABG in triple vessel disease

FAME - 3 trial. FFR guided PCI vs CABG in triple vessel disease

#FAME3 trial was recently published in #NEJM. Patients with three-vessel coronary artery disease have been found to have better outcomes with coronary-artery bypass grafting (#CABG) than with percutaneous coronary intervention (#PCI), but studies in which PCI is guided by measurement of fractional flow reserve (#FFR) have been lacking. The current trial tried to fill in the knowledge gap.
Nov 13, 202108:03
Device related thrombosis after LA appendage occlusion.

Device related thrombosis after LA appendage occlusion.

#DeviceRelatedThrombosis after #LeftAtrialAppendageOcclusion is a problem which negates the very advantages of left atrial appendage occlusion. It increases the ischemic risk. The #LAAODRTregistry was a case control study of device related thrombosis in patients who received any of the left atrial appendage occlusion device like Watchman or ACP/Amulet, published in JACC. Both #Watchman and #ACP or #Amulet device are associated with this complication of device related Thrombosis. This article was published in #JACC in July 2021, it discusses the predictors of device related thrombosis in patients with left atrial appendage occlusion device. It also evaluates the effect of device related thrombosis on mortality, ischemic risk and higher MACE. Let's take a dive into this article published in JACC and find out what the authors of LAAODRT registry concluded. #LAAODRTregistry #Watchman #ACP #Amulet #DeviceRelatedThrombosis Follow Cardio-Ed for more content. https://m.youtube.com/channel/UCVxInTblTpoy-THMuSxNyvw/videos Cardio-Ed is now available on Apple Poscast, Google Podcast, Spotify and other major podcast platforms too. Now you can stay updated on the go. Listen to episodes.(New episodes should be immediately avaliable on Spotify; would feature on other platforms in a while). Here are the links. Apple https://podcasts.apple.com/us/podcast/cardio-ed/id1570745864 Google Podcast https://podcasts.google.com/feed/aHR0cHM6Ly9hbmNob3IuZm0vcy81ZDRiOTgwMC9wb2RjYXN0L3Jzcw Spotify: https://open.spotify.com/show/3SLQ2g4Ii8hdFiy7i8LMRp?si=hWgPgwliQ5a5RY_nz-Q22g&utm_source=copy-link Amazon Music https://music.amazon.in/podcasts/4215cfdf-5121-438e-b355-14eaabed41e5/CARDIOED?ref=dm_sh_vn5xvDArGZGRCTh8YpK3Mdtff Stitcher: https://www.stitcher.com/podcast/cardioed Podcastaddict: https://podcastaddict.com/podcast/3368070 Breaker: https://www.breaker.audio/cardio-ed PocketCasts https://pca.st/bprb5899 RadioPublic https://radiopublic.com/cardioed-Woje3A Podcast Index https://podcastindex.org/podcast/3933141 Player FM https://player.fm/series/cardio-ed Listen Notes https://www.listennotes.com/podcasts/cardio-ed-cardio-ed-Jk3r1sq5_VF/ (Also available on Deezer)
Aug 01, 202108:19
Abelacimab for prevention of venous thromboembolism after knee replacement. NEJM 2021
Jul 26, 202105:58
ADAPTABLE TRIAL. aspirin doses for secondary prevention. NEJM 2021.
Jul 24, 202104:04
REHAB - HF trial & rehabilitation in older heart failure patients.

REHAB - HF trial & rehabilitation in older heart failure patients.

REHAB - HF trial was recently published in New England journal of medicine (NEJM) 2021 (July). It was also presented at the
American College of Cardiology Virtual Annual Scientific Session (ACC 2021).
The REHAB -HF trial tested the strategy of tailored rehabilitation program in older patients with acute heart failure.
Acute heart failure in older patients has its own problems.
In this podcast I discuss about the type of the patients enrolled in the REHAB - HF trial and its findings.
This important trial published in NEJM, july 2021 and presented at ACC 2021 is a landmark trial as far as the rehabilitation of heart failure patients is concerned.
To know more about the results of REHAB-HF trial published in NEJM 2021 and ACC 2021 listen to this podcast.
Jul 20, 202103:42
Omecamtiv mecarbil & GALACTIC-HF trial (NEJM 2021& JACC 2021)

Omecamtiv mecarbil & GALACTIC-HF trial (NEJM 2021& JACC 2021)

Role of omecamtiv mecarbil in heart failure with reduced ejection fraction (HFrEF) was published in GALACTIC- HF trial (NEJM 2021). Recently, in JACC the effect of ejection fraction on response to Omecamtiv mecarbil in patients enrolled in GALACTIC-HF trial was published.
In this presentation I have discussed both these studies together.
Omecamtiv mecarbil may find its place in newer guidelines for HFrEF.
To know more about Omecamtiv mecarbil in patients with HFrEF and both the trials published in NEJM and JACC listen to this podcast.
Jul 17, 202108:12
In stent restenosis - Risk factors, classification, restenosis, pathogenesis and management.

In stent restenosis - Risk factors, classification, restenosis, pathogenesis and management.

In stent restenosis is common after POBA. in the era of DES also, it is responsible for 10% of all PCI. In this podcast i have discussed about definition of ISR (in stent restenosis), classification of ISR (in stent restenosis), risk factors of ISR (in stent restenosis), investigations of ISR (in stent restenosis), management of ISR (in stent restenosis). What is the role of DAPT, drug coated balloon and drug eluting stent in management of ISR. What are the recommendations of EAPCI for ISR management.
When to use DEB? When to use DES?
Jul 03, 202131:30
TTM-2 Trial. Therapeutic hypothermia after cardiac arrest.

TTM-2 Trial. Therapeutic hypothermia after cardiac arrest.

Past, present and future of therapeutic hypothermia.

Targeted temperature management (TTM) or Therapeutic hypothermia is recommended for patients after cardiac arrest, but the supporting evidence is of low certainty.
TTM-2 trial was recently published in NEJM (June 2021).
The TTM-2 trial tried to answer the question if Therapeutic hypothermia is any better than normal temperature in patients who are in coma after being resuscitated from cardiac arrest.
I have briefly discussed the trial, also touching briefly the recent and upcoming trials of hypothermia protocol.



Do watch/ listen.

Jun 18, 202112:57
Heart Failure with Preserved Ejection Fraction: What works and what doesn't in 2021. (HFpEF- Tt)

Heart Failure with Preserved Ejection Fraction: What works and what doesn't in 2021. (HFpEF- Tt)

Heart Failure with Preserved Ejection Fraction (HFpEF) is responsible of more than half of the cases of heart failure. It is a difficult to diagnose and difficult to treat condition. In this lecture i have summarized the available and upcoming drugs and other treatment modalities and evidence supporting each decision we make in HFpEF management.
What should be the blood pressure of these patients? How to manage co-morbidities in HFpEF? What drugs to give? What treatments have no basis and should not be given? What drugs to watch out for in future? Is there anything else besides drugs and lifestyle management , which we can offer to the patients and is there any scientific basis of such treatment.
Jun 17, 202149:52
FLOWER - MI trial. FFR (vs CAG) in STEMI patients with multivessel disease

FLOWER - MI trial. FFR (vs CAG) in STEMI patients with multivessel disease

FLOWER- MI trial was published in NEJM May 2021.
The trial tested the strategy of FFR guided complete revascularization in STEMI and compared it to the angiography guided complete revascularization. I have discussed the trial in the podcast.
Jun 10, 202109:44
LAAOS-3 trial.

LAAOS-3 trial.

The LAAOS III was published in June 2021. The trial tested that if, on a background of anticoagulation, surgical left atrial appendage occlusion during cardiac surgery was beneficial or not. Do watch/ listen.
Jun 09, 202120:48
Role of SGLT-2 inhibitors in Heart Failure with reduced ejection fraction

Role of SGLT-2 inhibitors in Heart Failure with reduced ejection fraction

SGLT2 inhibitors are the new drugs which have been approved for heart failure with reduced ejection fraction (HFrEF). After the landmark EMPA-REG_OUTCOME, DECLARE TIMI 58, EMPEROR REDUCED and DAPA HF trials, empagliflozin and dapagliflozin have found a place in the management of HFrEF or heart failure. Lets discover what makes them special drugs in heart failure.
Jun 08, 202134:28
COVID-19 Vaccine-associated thrombosis

COVID-19 Vaccine-associated thrombosis

COVID-19 Vaccine Associated Thrombosis - What a medical practitioner should know? We have been listening about AstraZeneca vaccine associated thrombosis a lot. However, not much is known about this entity. I have tried to discuss Vaccine Associated Thrombosis in detail in this lecture. Do listen.
Jun 03, 202118:46
Anticoagulation in COVID-19 patients

Anticoagulation in COVID-19 patients

How to give anticoagulation in COVID-19 patients?
How to choose the right patient, and right drug?
How long to continue with anticoagulation in COVID19?
I try to answer these questions.
The presentation is not based on anecdotes/ experience.
There arent any trials i am discussing here.
Discussion strictly confined to International guidelines only.
May 29, 202119:41